Technology matters: The clinical utility of HPV mRNA testing compared to DNA testing

Article

Developments in cervical cancer screening have dramatically decreased disease incidence and mortality over the past few decades - but have also added confusion concerning the roles and clinical applications of new technologies that detect human papillomavirus (HPV). How should clinicians approach these new testing methods so that they can provide better quality of life and treatment planning for their patients?

In this online supplement, E. Marshall Austin, MD, PhD offers insights on the many questions clinicians may have about HPV testing modalities, including:

  • What is the role of HPV in cervical cancer?
  • How do performance data compare for HPV DNA and mRNA tests?
  • What are the benefits of HPV mRNA testing?

Read this online supplement to learn more about the latest in developments in cervical cancer screening.

Download Supplement

 

 

Recent Videos
HPV self-collection: Benefits, limitations, and future implications | Image Credit: forhers.com
Improving pediatric HPV vaccination rates: Early initiation and addressing disparities | Image Credit: blog.nemours.org.
New cervical cancer screening guidelines: What practitioners needs to know | Image Credit: forhers.com
COVID-19 Therapy Roundtable: Focusing on inpatient care
COVID-19 Therapy Roundtable: Defining the virus today and treatment options
How fezolinetant advances non-hormonal treatment of hot flashes | Image Credit: medschool.cuanschutz.edu
Contraceptive access challenges for college students in contraception deserts | Image Credit: linkedin.com.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.